Numinus Wellness To Undertake Phase 1 Study Of Psilocybin Extract

Numinus Wellness (TSXV: NUMI) is undertaking further studies of its psilocybin products. The company this morning announced a partnership with KGK Science, whereby it will begin studying a psilocybin extract produced in its lab.

The clinical trial is to study the safety and psychoactive properties of a Psilocybe mushroom product that has been extracted and formulated by the study. Classified as a phase 1 trial, the trial is to consist of 14 volunteers that will be used to assess the safety and efficacy of such a product, which will then be used in further trials, or under compassionate-use guidelines.

The study is expected to create IP for the company while also enabling further studies to be conducted in the future.

Numinus Wellness last traded at $1.08 on the TSX Venture.


Information for this briefing was found via Sedar and Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

Antimony Resources Drills 5.27% Sb Over 4.95 Metres In Latest Results

Nord Precious Metals Identifies 29 Veins At Castle East Following 3D Modeling

Related News

Numinus Wellness Receives Health Canada Amendment To Study Psilocybin Extraction

Numinus Wellness (TSXV: NUMI) this morning had a significant update, announcing that it has received...

Thursday, June 11, 2020, 09:10:28 AM

Numinus Wellness Sells Off Shares In Alto Neuroscience Ahead Of IPO

Numinus Wellness (TSX: NUMI) is reporting this morning that it has sold its interest in...

Thursday, February 1, 2024, 09:28:12 AM

Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin

Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an...

Thursday, April 22, 2021, 08:18:53 AM

Numinus Wellness Increases Financing To $15.0 Million

Numinus Wellness (TSXV: NUMI) has increased the size of the bought deal financing that it...

Monday, December 7, 2020, 10:46:35 AM

Numinus Wellness: A Glance At The Structure

The much anticipated launch of Numinus Wellness (TSXV: NUMI) is scheduled to occur tomorrow. Given...

Tuesday, May 19, 2020, 06:22:53 PM